Recent advances in the therapy of castration-resistant prostate cancer: The price of progress

Maturitas

Volumn 70, Issue 2, 2011, Pages 194-196

  Vasani, Dhwanishiva ^a   Josephson, David Y ^b   Carmichael, Courtney ^a   Sartor, Oliver ^c   Pal, Sumanta Kumar ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abiraterone; Cabazitaxel; Metastatic castration resistant prostate cancer; Sipuleucel T

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; ATRANSENTAN; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; DENOSUMAB; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; MITOXANTRONE; PREDNISONE; PROVENGE; RADIUM 223 CHLORIDE; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

BONE DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 80052557635     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2011.07.018     Document Type: Note

References (23)

1. FDA Approval for Docetaxel (Available at http://www.cancer.gov/ cancertopics/druginfo/fda-docetaxel; last accessed 17.06.11).
2. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
3. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
4. F. Saad, D.M. Gleason, and R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882 (Pubitemid 38807610)
5. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764 (Pubitemid 26185452)
6. E.S. Antonarakis, and M.A. Eisenberger Expanding treatment options for metastatic prostate cancer N Engl J Med 364 2011 2055 2058
7. O. Sartor, R.H. Reid, D.L. Bushnell, D.P. Quick, and P.J. Ell Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain Cancer 109 2007 637 643 (Pubitemid 46190974)
8. A.T. Porter, A.J. McEwan, and J.E. Powe Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer Int J Radiat Oncol Biol Phys 25 1993 805 813 (Pubitemid 23123384)
9. W.K. Kelly, S. Halabi, and M.A. Carducci A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 J Clin Oncol (Meeting Abstracts) 28 2010 LBA4511-
10. Scher HI, Chi KN, De Wit R, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): results from the phase III ASCENT2 trial. ASCO Meeting Abstracts 2010;28:4509.
11. Nelson JB, Fizazi K, Miller K, et al. Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). ASCO Meeting Abstracts 2011;29:117.
12. SWOG Press Release: NCI-supported SWOG trial S0421 closes early based on interim finding that atrasentan added to docetaxel and prednisone did not confer additional survival benefit to patients with hormone-refractory prostate cancer. (Available at http://www.swog.org/Members/Download/Bulletinboard/ Article200.pdf; last accessed 17.06.11.).
13. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
14. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
15. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
16. Alpharadin significantly improves overall survival in phase III trial in patients with castration-resistant prostate cancer that has spread to the bone. (Available at http://www.press.bayer.com/baynews/baynews.nsf/; last accessed 17.06.11.).
17. Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. ASCO Meeting Abstracts 2010; 28:LBA4507.
18. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (v.3.2011) (Available at http://www.nccn.org; last accessed 09.06.11.).
19. D.L. Longo Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 1966-8
20. Centers for Medicare & Medicaid Services. Proposed decision memo for autologous cellular immunotherapy treatment of metastatic prostate cancer (CAG-00422N). (Available at http://www.cms.gov+nca-proposed-decision-memo.aspx? NCAId=247&ver=11&NcaName=Autologous+Cellular+Immunotherapy; last accessed 17.06.11.).
21. Reminder: Medicare, Medicaid Are Gobbling Up the Budget (Available at http://blogs.wsj.com/health/2010/02/02/reminder-medicare-medicaid-are-gobbling- up-the-budget/; last accessed 17.06.11.).
22. J.D. Chambers, and P.J. Neumann Listening to provenge - what a costly cancer treatment says about future medicare policy N Engl J Med 364 2011 1687 1689
23. Pollack A. New drugs fight prostate cancer, but at High Cost The New York Times 2011 June 27.